Trial Profile
A Controlled, Randomised, Parallel, Multicentre Study to Assess Safety and Tolerability of the Oral Direct Thrombin Inhibitor AZD0837 in the Prevention of Stroke and other Thromboembolic Complications Associated with Atrial Fibrillation.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Sep 2015
Price :
$35
*
At a glance
- Drugs AZD 0837 (Primary) ; Warfarin
- Indications Stroke; Thromboembolism
- Focus Adverse reactions
- Sponsors AstraZeneca
- 05 Nov 2010 New trial record.